- Q3 revenue rose 16% YoY to $193M on 19% growth in active patients; net loss narrowed significantly YoY.
- Full-year 2026 guidance raised: revenue to $736M–$743M (prior: $710M–$725M) and Adj. EBITDA to $24M–$34M (prior: $0M–$15M).
- Optune Pax received approval in Japan for locally advanced pancreatic cancer.
?? Positive AI Sentiment (+6.8 / 10)